Woodstock Corp Reduces Position in Stryker Co. (NYSE:SYK)

Woodstock Corp trimmed its stake in Stryker Co. (NYSE:SYK - Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 15,346 shares of the medical technology company's stock after selling 873 shares during the period. Woodstock Corp's holdings in Stryker were worth $5,713,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $25,000. Capital A Wealth Management LLC purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $26,000. Rakuten Securities Inc. increased its position in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $30,000. Finally, BankPlus Trust Department purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Stryker stock traded up $1.04 during trading hours on Thursday, reaching $383.59. 371,658 shares of the stock were exchanged, compared to its average volume of 1,329,779. The company has a market cap of $146.41 billion, a P/E ratio of 49.43, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The stock has a 50 day moving average of $369.68 and a two-hundred day moving average of $376.11.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company posted $2.50 EPS. Equities analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's payout ratio is currently 45.41%.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a research report on Monday, May 5th. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a report on Tuesday, March 4th. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Finally, Roth Mkm raised their target price on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $427.30.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.